Probes for detection of human papillomavirus

• US 5,182,377 A
• Filed: 03/10/1989
• Issued: 01/26/1993
• Est. Priority Date: 09/09/1988
• Status: Expired due to Fees

• Current Assignee: Roche Molecular Systems Inc (Roche Holding AG)
• Original Assignee: Hoffmann-La Roche Incorporated (Roche Holding AG)
• Inventors: Ting, Yi, Manos, M. Michele, Wright, Deann K.
• Primary Examiner(s): Yarbrough, Amelia Burgess
• Assistant Examiner(s): Marschel, Ardin H.
• Application Number:
  US07/322,550
• Time in Patent Office: 1,418 Days
• Field of Search: 435/5, 435/6, 436/501, 436/811, 536/27, 935/3, 935/20, 935/77, 935/78
• US Class Current: 536/24.32
• CPC Class Codes: C12Q 1/686 Polymerase chain reaction [PCR]
• CPC Class Codes: C12Q 1/708 for papilloma
• CPC Class Codes: Y10S 435/81 Packaged device or kit
• CPC Class Codes: Y10S 436/811 Test for named disease, body condition or organ function

Abstract

The presence of human papillomavirus (HPV) in a sample can be detected and the HPV typed by a method that involves the amplification of HPV DNA sequences by the polymerase chain reaction (PCR). The primers used in the method are consensus primers that can be used to amplify a particular region of the genome of any HPV. The presence of HPV in a sample is indicated by the formation of amplified DNA. The HPV is typed by the use of type-specific DNA probes specific for the amplified region of DNA.

Claims

1. AN HPV L1 consensus probe selected from the group consisting of probes MY66, MY55, MY39, MY56, and MY57.